ECRAID-Prime is a multi-country collaboration built on strong clinical and academic relationships.
Spanning 12 countries, the ECRAID-Prime consortium is made up of Ecraid, University Medical Center Utrecht (UMCU), the University of Oxford, the University of Antwerp, European Clinical Research Infrastructure Network (ECRIN), and the Norwegian Institute of Public Health.
ECRAID-Prime is part of Europe's Joint Access Advisory Mechanism (JAAM) and the Trial Coordination Board (TCB).
- The Joint Access Advisory Mechanism (JAAM) provides a gateway to COVID-19 adaptive platform trials taking place in Europe.
JAAM assesses requests from investigators and industry who are looking to test their compounds in one or more of these trials.
- The Trial Coordination Board (TCB) enables regular dialogue between the platform trials in Europe. By participating in the TCB, ECRAID-Prime can discuss issues related to trial design, conduct and implication of results with trialists and stakeholders from wider research network, and support research harmonisation in Europe.
We look forward to working with a range of partners to implement unique earlier phase research for the community treatment of COVID-19 and COVID-like illness.